Rifampicin - AlphaRx

Drug Profile

Rifampicin - AlphaRx

Alternative Names: Rifampicin nanoparticles - AlphaRx; Rifamsolin

Latest Information Update: 23 Sep 2011

Price : $50

At a glance

  • Originator AlphaRx
  • Class Antibacterials; Antineoplastics; Antituberculars; Hepatoprotectants; Rifamycins
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Tuberculosis

Most Recent Events

  • 05 Jul 2011 Discontinued - Preclinical for Tuberculosis in Canada (PO)
  • 27 May 2008 AlphaRx establishes CRADA with US Army for the development of antibacterial nanoparticles in severe intracellular bacterial infections
  • 07 Feb 2005 Preclinical trials in Tuberculosis in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top